HHMI
MYGN icon

Howard Hughes Medical Institute’s Myriad Genetics MYGN Stock Holding History

Howard Hughes Medical Institute’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,010
Closed -$39K – 186
2014
Q3 		$39K Buy
+1,010
New +$37.7K 0.01% 164

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Howard Hughes Medical Institute's MYGN Position: Q4 2014 in Review

Howard Hughes Medical Institute sold out of Myriad Genetics (MYGN) in Q4 2014, closing a stake of 1,010 shares — an estimated $39K sold.

Howard Hughes Medical Institute first reported a position in MYGN in Q3 2014 and held it in 1 quarter. The position peaked at $39K in Q3 2014. 273 funds tracked by Wall St. Rank hold MYGN as of Q4 2014.

  • Howard Hughes Medical Institute reported no remaining Myriad Genetics position as of Q4 2014 after selling out during the quarter.
  • Howard Hughes Medical Institute sold 1,010 Myriad Genetics shares in Q4 2014, an estimated $39K.
  • Howard Hughes Medical Institute first reported a position in Myriad Genetics in Q3 2014 and held it in 1 quarter.
  • Howard Hughes Medical Institute's Myriad Genetics position peaked at $39K in Q3 2014.
  • 273 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2014.

Based on Howard Hughes Medical Institute's 13F filing for Q4 2014, filed 11 Feb 2015.